MIRA

+ Watchlist + Portfolio

MIRA Pharmaceuticals, Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.73
52-Week Range: $0.60 – $2.45
Market Cap: $30.56M
P/E (TTM): —
EPS (TTM): -1.14
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 3.75
PEG Ratio: —
Return on Equity: -217.12%
Return on Assets: -129.55%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 200.08
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-1.01M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $22.57M

MIRA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$2.35M	$1.57M	$3.31M	$1.72M
Selling, General & Admin	$2.99M	$6.50M	$4.71M	$8.77M
Operating Expenses	$7.05M	$8.53M	$8.02M	$10.49M
Operating Income	-$7.05M	-$8.53M	-$8.02M	-$10.49M
EBITDA	-$7.05M	-$8.53M	-$8.02M	-$10.49M
Pretax Income	-$7.06M	-$11.98M	-$7.85M	-$10.44M
Net Income	-$7.06M	-$11.98M	-$7.85M	-$10.44M
Diluted EPS	-0.40	-0.85	-0.51	-1.35
Diluted Shares	17.75M	13.92M	15.44M	23.69M

MIRA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$350.98K	$4.60M	$2.83M	$6.35M
Receivables	$0.00	$11.86K	$0.00	—
Current Assets	$494.40K	$4.86M	$2.89M	$11.06M
Total Assets	$858.07K	$4.93M	$2.92M	$11.09M
Current Liabilities	$1.37M	$558.10K	$723.35K	$702.07K
Total Debt	$491.23K	$5.06K	$0.00	—
Total Liabilities	$1.45M	$558.10K	$723.35K	$702.07K
Retained Earnings	-$9.30M	-$21.29M	-$29.14M	-$39.58M
Shareholders' Equity	-$596.23K	$4.37M	$2.20M	$10.39M
Working Capital	-$875.63K	$4.30M	$2.16M	$10.36M

MIRA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$5.60M	-$4.53M	-$5.56M	-$4.66M
Free Cash Flow	-$5.60M	-$4.53M	-$5.56M	-$4.66M
Stock-Based Compensation	$1.30M	$2.55M	$1.92M	$6.31M
Financing Cash Flow	$3.15M	$8.78M	$3.79M	$8.18M
Net Change in Cash	-$2.46M	$4.25M	-$1.77M	$3.51M

MIRA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$314.40K	$496.20K	$412.64K	$496.54K	$524.78K	$705.79K
Selling, General & Admin	$1.49M	$1.05M	$904.35K	$5.33M	$578.70K	$450.33K
Operating Expenses	$1.81M	$1.55M	$1.32M	$5.82M	$1.10M	$1.16M
Operating Income	-$1.81M	-$1.55M	-$1.32M	-$5.82M	-$1.10M	-$1.16M
EBITDA	-$1.81M	-$1.55M	-$1.32M	-$5.82M	-$1.10M	-$1.16M
Pretax Income	-$1.78M	-$1.54M	-$1.14M	-$5.98M	-$1.15M	-$1.21M
Net Income	-$1.78M	-$1.54M	-$1.14M	-$5.98M	-$1.15M	-$1.21M
Diluted EPS	-0.11	-0.09	-1.18	—	-0.03	-0.03
Diluted Shares	16.65M	16.99M	19.27M	—	41.94M	42.02M

MIRA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$1.21M	$730.48K	$2.64M	$6.35M	$4.82M	$3.61M
Current Assets	$1.36M	$832.88K	$7.60M	$11.06M	$9.43M	$8.17M
Total Assets	$1.40M	$868.32K	$7.63M	$11.09M	$9.46M	$8.20M
Current Liabilities	$106.17K	$298.46K	$83.93K	$702.07K	$114.76K	$40.82K
Total Liabilities	$106.17K	$298.46K	$83.93K	$702.07K	$114.76K	$40.82K
Retained Earnings	-$30.92M	-$32.46M	-$33.60M	-$39.58M	-$40.73M	-$41.94M
Shareholders' Equity	$1.29M	$569.86K	$7.55M	$10.39M	$9.35M	$8.16M
Working Capital	$1.26M	$534.42K	$7.51M	$10.36M	$9.31M	$8.13M

MIRA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$1.63M	-$799.65K	-$1.10M	-$1.14M	-$1.20M	-$1.21M
Free Cash Flow	-$1.63M	-$799.65K	-$1.10M	-$1.14M	-$1.20M	-$1.21M
Stock-Based Compensation	$874.81K	$489.57K	$390.84K	$4.56M	$107.59K	$21.88K
Financing Cash Flow	$3.38K	$323.84K	$3.01M	$4.84M	-$330.61K	$0.00
Net Change in Cash	-$1.63M	-$475.81K	$1.91M	$3.71M	-$1.53M	-$1.21M

Market Snapshot

About

MIRA Pharmaceuticals is a pre-clinical biotech company developing cannabinoid-based therapies. The company focuses on novel drug candidates for neurological disorders and other medical conditions.